• Explore /
  • Poster
  • / Checkmate 816: A phase 3, randomized, open-label trial of nivolumab plus ipilimumab vs platinum-doublet chemotherapy as neoadjuvant treatment for early-stage NSCLC.

Checkmate 816: A phase 3, randomized, open-label trial of nivolumab plus ipilimumab vs platinum-doublet chemotherapy as neoadjuvant treatment for early-stage NSCLC.

Abstract Poster

Authors

Patrick Forde

Patrick M. Forde

Johns Hopkins Kimmel Cancer Center and Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, MD

Patrick M. Forde , Jamie E. Chaft , Enriqueta Felip , Stephen Broderick , Nicolas Girard , Mark M. Awad , Keith Kerr , Anne Blackwood-Chirchir , Rong Yang , William J. Geese , Julie R. Brahmer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Adjuvant Therapy

Clinical Trial Registration Number

NCT02998528

Citation

J Clin Oncol 35, 2017 (suppl; abstr TPS8577)

DOI

10.1200/JCO.2017.35.15_suppl.TPS8577

Abstract #

TPS8577

Poster Bd #

312a

Abstract Disclosures

Similar Posters

First Author: Matt D. Galsky

First Author: Matt D. Galsky

First Author: Gerard Zalcman

First Author: Yan Feng